{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041274","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.743736+00:00","generated_at":"2026-06-11T17:54:59.849100+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amylyx Q2 product revenue $98.2M, net income $22.1M; CHMP re-examining MAA","bullets":["Net product revenue $98.2M in Q2 2023 (up from $71.4M in Q1); net income $22.1M ($0.31 diluted EPS).","Cash, equivalents and short-term investments $357.3M at June 30, 2023.","Phase 3 ORION trial of AMX0035 for PSP to start by year-end; ~600 participants planned.","CHMP re-examining negative opinion on AMX0035 MAA for ALS; final opinion expected fall 2023.","Five Canadian provinces now reimburse ALBRIOZA; broad public coverage expected by end of August."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041274","json":"https://secwatch.observer/filing/0000950170-23-041274.json","markdown":"https://secwatch.observer/filing/0000950170-23-041274.md","text":"https://secwatch.observer/filing/0000950170-23-041274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/0000950170-23-041274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/amlx-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:54:59.849100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ecaf668f347beb5935ddbb7e4a64195d86180770","claim":"Amylyx Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $98.2 million, net income $22.1 million, EPS $0.31 on a fully diluted per share basis.","evidence_excerpt":"in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZATM in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/0000950170-23-041274-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$98.2 million"},{"label":"Net income","value":"$22.1 million"},{"label":"EPS","value":"$0.31 on a fully diluted per share basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}